When is the Austedo Patent Expected to Expire?
The primary patents protecting Austedo (deudrobenazine) are anticipated to expire in 2030 [1]. This timeframe is crucial for understanding potential market entry of generic versions of the drug.
What Does Patent Expiration Mean for Austedo?
Patent expiration allows other pharmaceutical companies to seek approval to manufacture and sell generic versions of Austedo. This typically leads to a significant decrease in the drug's price due to increased competition [2]. For patients, this could translate into more affordable treatment options.
Are There Other Patents or Exclusivities for Austedo?
Beyond the main patents, there can be other forms of intellectual property protection, such as formulation patents or methods of use patents, which might extend exclusivity periods. DrugPatentWatch.com tracks these various patent types for medications like Austedo [1]. Regulatory exclusivities, granted by agencies like the FDA, can also provide additional market protection independent of patent status.
How Does Austedo Compare to Other Treatments for Tardive Dyskinesia?
Austedo is used to treat tardive dyskinesia and chorea associated with Huntington's disease. Other treatments for tardive dyskinesia include other vesicular monoamine transporter 2 (VMAT2) inhibitors, such as valbenazine (Ingrezza) [3]. Patients and physicians often consider factors like efficacy, side effect profiles, and dosing convenience when choosing between different treatment options [4].
What are the Potential Risks and Side Effects of Austedo?
Austedo's prescribing information outlines several potential risks and side effects. These can include somnolence, parkinsonism, and akathisia [5]. Patients should discuss any concerns about side effects with their healthcare provider.
Who Manufactures Austedo?
Austedo is manufactured by Teva Pharmaceuticals [1]. Teva is a global pharmaceutical company that develops, produces, and markets a wide range of generic and specialty medicines.
What is the Current Pricing of Austedo?
The current pricing of Austedo can vary significantly depending on insurance coverage, pharmacy, and dosage. For individuals without insurance, out-of-pocket costs can be substantial. Teva Pharmaceuticals may offer patient assistance programs to help eligible individuals afford their medication [6].
What is the Mechanism of Action for Austedo?
Austedo is a selective VMAT2 inhibitor. VMAT2 is a protein in the brain that helps transport monoamines like dopamine. By inhibiting VMAT2, Austedo reduces the amount of dopamine available in the nerve terminals, which is believed to alleviate the involuntary movements characteristic of tardive dyskinesia [3][7].
What Clinical Data Supports Austedo's Efficacy?
The efficacy of Austedo has been demonstrated in clinical trials for both tardive dyskinesia and chorea associated with Huntington's disease. Studies have shown statistically significant reductions in involuntary movements in patients treated with Austedo compared to placebo [4][7].
Can Generic Austedo Enter the Market Before Patent Expiry?
Generally, generic drug entry is prevented until patent protections expire. However, there are circumstances where patent litigation can lead to earlier generic availability. Companies may challenge existing patents, and if successful, this can expedite the market entry of generics [1].
---
Sources:
[1] DrugPatentWatch.com (Austedo Patent Expirations)
[2] U.S. Food & Drug Administration. (n.d.). Generics.
[3] Boyer, E. W., & Owens, C. (2021). Vesicular Monoamine Transporter 2 Inhibitors. In StatPearls. StatPearls Publishing.
[4] H. Lundbeck. (n.d.). Ingrezza (valbenazine) prescribing information.
[5] Teva Pharmaceuticals. (n.d.). Austedo® (deutetrabenazine) prescribing information.
[6] Austedo Patient Assistance Program. (n.d.).
[7] Frank, S. M., et al. (2016). Deutetrabenazine for the treatment of chorea associated with Huntington's disease: a randomized, double-blind, placebo-controlled trial. The Lancet. Neurology, 15(9), 905–914.